LONGBIO-B(01779) pricing IPO at HK$96.06 X

28/05/2026 14:57

(Infocast News)   Clinical-stage biopharmaceutical company LongBio Pharma (Suzhou) Co., Ltd.(01779) starts its initial public offering (IPO) today. The details are as follows:

Number of Shares Offered: 14,193,155 H shares, comprising 12,773,800 shares (90%) for international placing and 1,419,355 shares (10%) for the Hong Kong public offer, with a 15% over-allotment option.

Offer Price: HK$96.06

Gross Proceeds: HK$1.3634 billion

Net Proceeds: HK$1.2549 billion

Use of Proceeds:
- Approximately 75.0%, or HK$941.2 million, will be used primarily for the R&D and commercialization of our Core Product and Key Product, (including: Approximately 34.0%, or HK$426.7 million, will be used for the R&D of our Core Product LP-003；Approximately 13.0%, or HK$163.1 million, will be used for the commercialization of LP-003 for seasonal AR indications in China over the next three to five years；Approximately 28.0%, or HK$351.4 million, will be used for the R&D of our Key Product LP-005)
- Approximately 15.0%, or HK$188.2 million, will be used for further development of our other pre-clinical pipeline products and our R&D platforms,
-  Approximately 10.0%, or HK$125.5 million, will be used for working capital and other general corporate purposes.

Cornerstone Investors           (Investment Amount)

OrbiMed Funds:                 US$18.0 million
TruMed Funds:                  US$12.0 million
Huatai Capital Investment and its ultimate clients: US$20.0 million
Foresight Fund (Ruiyuan):      US$10.0 million
Fullgoal Fund:                  US$10.0 million
Value Partners:                 US$8.0 million
Mega Prime(wholly owned by GBAHIL): US$5.0 million
FR M CONSULTING:                US$2.0 million
CPE Greater China Enterprises Growth Fund and China Galaxy International Investment (in respect of CPE OTC Swap): US$2.0 million
Total:                     US$87.0 million (approx. HK$681.1 million)

*Note: Cornerstone investors are subject to a 6-month lock-up period.

Board Lot Size: 50 shares

IPO Entry Fee: HK$4,851.44

Offer Period: May 28, 2026 to June 2, 2026 at 12:00 noon

Listing Date: June 5, 2026

Sponsor: Sinolink Securities (Hong Kong)

eIPO Services: www.hkeipo.hk and HKEX's FINI system. (SY)

Infocast Limited and its information providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.